COMPASS Pathways plc (ticker: CMPS) recently announced that its innovative therapy Comp360 psilocybin for treatment-resistant depression has successfully achieved the primary endpoint in the second pivotal Phase 3 clinical trial.

COMPASS Pathways plc (ticker: CMPS) recently announced that its innovative therapy Comp360 psilocybin for treatment-resistant depression has successfully achieved the primary endpoint in the second pivotal Phase 3 clinical trial.

老虎证券2026/02/17 11:44

Show original

This groundbreaking development marks a solid step forward in validating the safety and efficacy of this therapy, bringing new hope to millions of patients worldwide suffering from treatment-resistant depression.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

COMPASS Pathways plc (ticker: CMPS) recently announced that its innovative therapy Comp360 psilocybin for treatment-resistant depression has successfully achieved the primary endpoint in the second pivotal Phase 3 clinical trial.

You may also like

Trending news

Crypto prices